TRYPTAN TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

TRYPTOPHAN

Pieejams no:

BAUSCH HEALTH, CANADA INC.

ATĶ kods:

N06AX02

SNN (starptautisko nepatentēto nosaukumu):

TRYPTOPHAN

Deva:

750MG

Zāļu forma:

TABLET

Kompozīcija:

TRYPTOPHAN 750MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Ārstniecības joma:

MISCELLANEOUS ANTIDEPRESSANTS

Produktu pārskats:

Active ingredient group (AIG) number: 0111038005; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2021-06-11

Produkta apraksts

_Pr_
_TRYPTAN_
_®_
_ L-Tryptophan Product Monograph Page 1 of 15_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TRYPTAN
®
L-Tryptophan
250 mg; 500 mg; 750 mg tablets
1 g Tablets
500 mg Capsules
Oral
Adjunct in the Management of Affective Disorders
Bausch Health, Canada Inc.
Date of Initial Authorization:
2150 St-Elzear Blvd. West
February 23, 1994
Laval, Quebec
H7L 4A8
Date of Revision:
June 9, 2021
Submission Control Number: 247785
_ _
_Pr_
_TRYPTAN_
_®_
_ L-Tryptophan Product Monograph Page 2 of 15_
RECENT MAJOR LABEL CHANGES
NONE
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT
LISTED.
RECENT MAJOR LABEL CHANGES
....................................................................................
2
TABLE OF CONTENTS
.........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................................
4
1
INDICATIONS.............................................................................................................
4
2
CONTRAINDICATIONS
..............................................................................................
4
4
DOSAGE AND ADMINISTRATION
.............................................................................
4
4.2
Recommended Dose and Dosage Adjustment
................................................... 4
4.4
Administration....................................................................................................
4
5
OVERDOSAGE
..........................................................................................................
5
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
....................... 5
7
WARNINGS AND PRECAUTIONS
.............................................................................
6
8
ADVERSE REACTIONS
.............................................................................................
7
8.1
Adverse Reaction Overview
.............